Danaher Corporation
DHR Healthcare Diagnostics & Research
Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024. In the quarter to June 2026, revenue grew 5.54%, EPS grew 59.7%, free cash flow grew 15.6% and total debt rose 49.2%, each against the same quarter a year earlier. Member of the S&P 500.
Follow DHR
Danaher Corporation (DHR) Return on invested capital
Danaher Corporation's return on invested capital over the twelve months to 30 June 2026 was 4.37%, down 0.1 percentage points from fiscal 2025 (4.42%). Over the past ten years it has ranged from 3.86% (fiscal 2015) to 7.45% (fiscal 2022); the current reading is higher than 18% of that period. That is above the Diagnostics & Research industry median of 0.00% and above the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 4.42% | (0.41) |
| FY2024 | 4.83% | (0.22) |
| FY2023 | 5.05% | (2.40) |
| FY2022 | 7.45% | 1.30 |
| FY2021 | 6.15% | 1.34 |
| FY2020 | 4.81% | (1.60) |
| FY2019 | 6.41% | 1.27 |
| FY2018 | 5.14% | 0.68 |
| FY2017 | 4.46% | (0.92) |
| FY2016 | 5.38% | 1.52 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| IDXX IDEXX Laboratories, Inc. compare | 48.9% |
| MTD Mettler-Toledo International, Inc. compare | 35.4% |
| ILMN Illumina, Inc. compare | 17.5% |
| A Agilent Technologies, Inc. compare | 11.1% |
| IQV IQVIA Holdings Inc. compare | 6.80% |
| TMO Thermo Fisher Scientific Inc. compare | 5.80% |
| DHR Danaher Corporation | 4.37% |
| WAT Waters Corporation compare | 1.05% |
| NTRA Natera, Inc. compare | −22.3% |
| Diagnostics & Research industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)
More on DHR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement